Local drug delivery and gene therapy;Lokale Medikamentengabe und Gentherapie

Herz

Volumn 22, Issue 6, 1997, Pages 347-354

  Darius, H ^a,b   Buerke, M ^a   Boissel, J P ^a   Grosser, T ^a   Veit, K ^a   Zacharowski, K ^a   Meyer, J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Gene transfer; Inhibition of proliferation; Local drug delivery; Restenoses

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE;

ARTERY INTIMA PROLIFERATION; CELL CYCLE; DRUG DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; REPORTER GENE; RESTENOSIS; REVIEW;

EID: 0031411653     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044285     Document Type: Review

References (26)

1. Bertrand ME, Allain H, Lablanche JM on behalf of the investigators of the TACT study. Results of a randomized trial of ticlopidine versus placebo for prevention of acute closure and restenosis after coronary angioplasty (PTCA) The TACT study. Circulation 1990;82:Suppl:754.
2. Davis RJ. The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993;268:10501-6.
3. Dichek DA, Anderson J, Kelly AB, Hanson SR, Harker LA. Enhanced in vivo antithrombotic effects of endothelial cells expressing recombinant plasminogen activators transduced with retroviral vectors. Circulation 1996;93:301-9.
4. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:9561.
5. Fernandez-Ortiz A, Meyer BJ, Mailhac A, et al. A new approach for local intravascular drug delivery. Circulation 1994;89:1518-22.
6. Fuster V. Lewis O'Conner Memorial Lecture: mechanisms leading to myocardial infarction. insights from studies of vascular biology. Circulation 1994;90:2126-46.
7. Gonschior P, Goetz AE, Huehns TY, Hofling B. A new catheter für prolonged local drug application. Cor Art Dis 1995;6:329-34.
8. Gonschior P, Pahl C, Huehns TY, Gerhauser F, Erdemci A, Larisch K, Dellian M, Deil S, Goetz AE, Lehr HA, Höfling B. Comparison of local intravascular drug-delivery catheter systems. Am Heart J 1995;130:1174-81.
9. Höfling B, Huehns TY. Clinical perspective: Intravascular local drug delivery after angioplasty. Eur Heart J 1995;16:437-40.
10. Lablanche JM, Grollier G, Lusson JR, et al. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD study. Circulation 1997;95:83-9.
11. Landau C, Lange RA, Hillis D. Percutaneous transluminal coronary angioplasty. N Engl J Med 1994;330:981-93.
12. Lincoff AM, Topol EJ, Ellis SG. Local drug delivery for the prevention of restenosis. Fact, fancy, and future. Circulation 1994;90:2070-84.
13. Maresta A, Balducelli M, Cantini L, et al. Trapidil (triazolopyrimidine), a platelet derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Circulation 1994;90:2710-5.
14. Murphy JG, Schwarz RS, Edwards WD, Camrud AR, Vliestra RE, Holmes DR. Percutaneous polymeric stents in porcine coronary arteries. Circulation 1992;86:1596-604.
15. Nabel EG, Yang G, Liptay S, et al. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest 1993;91:1822-9.
16. Riessen R, Isner JM. Prospects for the site-specific delivery of pharmacologic and molecular therapies. J Am Coll Cardiol 1994;23:1234-44.
17. Schini-Kerth VB, Fisslthaler B. van Obberghen-Schilling E, Busse R. Serotonin stimulates the expression of thrombin receptors in cultured vascular smooth muscle cells. Role of protein kinase C and protein tyrosine kinase. Circulation 1996;93:2170-7.
18. Schwartz L, Bourasse MG. Lespérance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-9.
19. Scott-Burden T, Vanhoutte PM. The endothelium as a regulator of vascular smooth musc le proliferation. Circulation 1993;87: Suppl.V:V-51-5.
20. Shi Y, Fard A, Galeo A, et al. Transcatheter delivery of c-myc antisense oligomers reduces neointima formation in a porcine model of coronary artery balloon injury. Circulation 1994;93:820-8.
21. Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994;43:881-6.
22. Tradif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med 1997;337:365-72
23. Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene transfer of naked DNA encodong vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996;94:3281-90.
24. von der Leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92:1137-41.
25. Wolinsky H, Thung SN. Use of the perforated balloon catheter to deliver concentrated heparin into the wall of normal canine artery. J Am Coll Cardiol 1990;15:475-81.
26. Zucker TP, Grosser T, Morinelli T, et al.Potentiation PDGF-induced growth responses in coronary artery smooth muscle cells by thromboxane. Agents and Actions 1995;45:Suppl:53-8.